Roth Capital analyst Kyle Bauser raised the firm’s price target on iRadimed (IRMD) to $98 from $90 and keeps a Buy rating on the shares, citing higher forward estimates and confidence in the business after the company reported Q3 sales and EPS above the firm’s and consensus estimates and raised full-year guidance.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRMD: